CV CapsoVision
Price Chart
Executive Summary
CapsoVision reported Q4 and full-year 2025 earnings with revenue growth of 13% and 15% respectively, driven by increased capsule sales. Despite top-line growth, the company widened its net loss to $25.3M from $19.9M in 2024 due to higher R&D and public company expenses. It bolstered its cash position with a $14M private placement in March 2026, following its July 2025 IPO which generated $23.4M in net proceeds.
Key Financial Metrics
Actionable Insight
The stock may react positively to revenue growth and AI/FDA momentum, but traders should monitor whether rising R&D spend translates into near-term commercialization. The recent $14M financing alleviates near-term liquidity concerns, but path to profitability remains distant.
Key Facts
- Q4 2025 revenue: $3.9M (+13% YoY), full-year 2025 revenue: $13.6M (+15% YoY)
- Gross margin held at 50% in Q4, full-year 2025 margin was 53% (down from 54% in 2024)
- Operating expenses rose to $32.7M in 2025 (+25% YoY), driven by R&D under Canon partnership and public company costs
- Net loss widened to $25.3M in 2025 from $19.9M in 2024; EPS was -$1.03 vs. -$9.85 (outstanding shares increased due to IPO)
- Cash and equivalents: $10.1M as of Dec 31, 2025; $14M private placement completed March 16, 2026
- Submitted 510(k) for AI-assisted module for CapsoCam Plus; advancing next-gen colon and pancreas capsule programs
Financial Impact
Revenue increased by $1.8M year-over-year, but operating losses expanded by $5.6M. Cash runway extended by $14M private placement post-year-end.
Risk Factors
- Continuing operating losses and negative cash flow from operations ($22.9M used in 2025)
- Heavy reliance on future regulatory approvals (FDA 510(k) for AI module not yet cleared)
- Dilution risk from future financings given current burn rate and limited cash
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263416 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 30, 2026
20d ago
|
Press Release
| $7.50 $7.19 | ▼ −4.13% | ▼ −6.48% | $6.47 (−13.73%) |
|
Apr 23, 2026
28d ago
|
EFFECT
| $5.77 $6.40 | ▲ +10.92% | ▲ +9.44% | $6.47 (+12.13%) |
|
Apr 17, 2026
4w ago
|
S-1
| $6.01 $6.37 | ▲ +5.99% | ▲ +5.08% | $6.47 (+7.65%) |
|
Mar 26, 2026
7w ago
|
Press Release
| $7.51 $6.70 | ▼ −10.79% | ▼ −14.65% | $6.47 (−13.85%) |
|
Mar 20, 2026
8w ago
|
Press Release
| $6.87 $7.51 | ▲ +9.32% | ▲ +11.47% | $6.47 (−5.82%) |
|
Mar 12, 2026
9w ago
|
Press Release
| $5.52 $6.87 | ▲ +24.46% | ▲ +26.57% | $6.47 (+17.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access